Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026

PUBT · 2d ago
Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026
  • Zevra flagged new long-term real-world findings for MIPLYFFA in Niemann-Pick type C, slated for presentation at the 2026 SSIEM symposium.
  • Expanded access data indicated sustained disease stabilization over multiple years across children and adults, supporting earlier trial evidence of slower progression.
  • German compassionate-use experience showed long treatment exposure with no treatment-related discontinuations, reinforcing the drug’s tolerability in routine practice.
  • Some patients worsened quickly when therapy stopped, a signal that could strengthen the case for continued long-term use in clinical care.
  • MIPLYFFA is FDA-cleared for neurological manifestations of NPC in patients aged 2 and older when used with miglustat, underpinning Zevra’s commercial strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250730PRIMZONEFULLFEED9815143) on August 25, 2026, and is solely responsible for the information contained therein.